Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan

SHOTARO YASUOKA; TAKESHI YUASA; MASAHIRO OGAWA; YOSHINOBU KOMAI; NOBORU NUMAO; SHINYA YAMAMOTO; YUKIHIRO KONDO; JUNJI YONESE

doi:10.21873/anticanres.13784

Article Figures & Data

Figures

Tables

Download figure
Open in new tab
Download powerpoint
Figure 1.
Efficacy of cabazitaxel as second or later-line treatment for the studied Japanese patients (n=44) with docetaxel chemotherapy-resistant metastatic castration-resistant prostate cancer. Waterfall plots of the prostate-specific antigen (PSA) response (A). Progression-free survival (PFS) and overall survival (OS) curves for the study cohort are shown (B, C).
Download figure
Open in new tab
Download powerpoint
Figure 2.
Risk factors for short survival period at induction of cabazitaxel therapy. On multivariate analysis, <10 prior cycles of docetaxel (A), lower haemoglobin concentration (<10 g/dl) (B), and higher serum prostate-specific antigen (PSA) level (>100 ng/ml) (C) were shown as independent factors predictive of a shorter overall survival (OS) period. Our prognostic model, which includes 3 risk factors, namely poor performance status (≥2), presence of liver metastasis, and elevated C-reactive protein levels (>upper limit of the normal range), stratifies patients treated with cabazitaxel into three risk groups [good: 0 risk factors, n=14 (35%); intermediate: 1 risk factor, n=18 (45%); and poor: ≥2 risk factors, n=8 (20%)] (C).The prognostic model distinctly separates the OS curves of the three risk groups (p<0.001).
Download figure
Open in new tab
Download powerpoint
Figure 3.
Biomarkers for overall survival with cabazitaxel therapy. Median overall survival (OS) period of patients who had a prostate-specific antigen (PSA) response ≥50% is 30 months, whereas that of the patients whose PSA response was not ≥50% is 12 months (p=0.0013).